CorMedix announce CMA granted TDAPA to DefenCath

CorMedix announced that the Center for Medicare & Medicaid Services, CMS, has determined that DefenCath meets the criteria for a Transitional Drug Add-On Payment, TDAPA, in the anti-infective functional category, beginning on July 1, 2024. The TDAPA program currently provides for five years of additional payment reimbursement beyond the ESRD bundled rate to outpatient providers, and aligns with CorMedix’s upcoming outpatient launch in July. Joseph Todisco, Chief Executive Officer of CorMedix commented, “CMS determination of TDAPA eligibility for DefenCath is a critical step toward ensuring this innovative preventative drug product is available for patients in the outpatient dialysis setting. We are pleased that CMS was able to take timely action on our application for a July 1st effective date, and we intend to work closely with outpatient dialysis providers to ensure proper TDAPA implementation.”